EA202190895A1 - Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке - Google Patents

Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке

Info

Publication number
EA202190895A1
EA202190895A1 EA202190895A EA202190895A EA202190895A1 EA 202190895 A1 EA202190895 A1 EA 202190895A1 EA 202190895 A EA202190895 A EA 202190895A EA 202190895 A EA202190895 A EA 202190895A EA 202190895 A1 EA202190895 A1 EA 202190895A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell
nucleic acids
expression
lpa expression
inhibiting lpa
Prior art date
Application number
EA202190895A
Other languages
English (en)
Inventor
Давид Антони Ридер
Лукас БЕТГЕ
Кристиан Фрауэндорф
Адриен Вайнгертнер
Юдит Хауптман
Зибилле Дамес
Штеффен Шуберт
Штефан Тенбаум
Original Assignee
Сайленс Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайленс Терапьютикс Гмбх filed Critical Сайленс Терапьютикс Гмбх
Publication of EA202190895A1 publication Critical patent/EA202190895A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

В настоящем изобретении предложены продукты и композиции, а также варианты их применения. В частности, в настоящем изобретении предложены продукты нуклеиновой кислоты, которые препятствуют экспрессии гена LPA или ингибируют его экспрессию, предпочтительно для применения в качестве лечения, предотвращения или уменьшения риска развития сердечно-сосудистого заболевания, такого как ишемическая болезнь сердца, или стеноз аорты, или инсульт, или любого другого нарушения, патологии или синдрома, связанных с повышенными уровнями частиц Lp(a).
EA202190895A 2019-05-14 2019-11-13 Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке EA202190895A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
EA202190895A1 true EA202190895A1 (ru) 2021-08-10

Family

ID=66554180

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190895A EA202190895A1 (ru) 2019-05-14 2019-11-13 Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке

Country Status (29)

Country Link
US (2) US20220002722A1 (ru)
EP (2) EP3880818B1 (ru)
JP (1) JP7245328B2 (ru)
KR (1) KR102553386B1 (ru)
CN (1) CN113227372A (ru)
AU (1) AU2019380628A1 (ru)
BR (1) BR112021009213A2 (ru)
CA (1) CA3119239A1 (ru)
CL (1) CL2021001225A1 (ru)
CO (1) CO2021007372A2 (ru)
CR (1) CR20210301A (ru)
DK (1) DK3880818T3 (ru)
EA (1) EA202190895A1 (ru)
ES (1) ES2932295T3 (ru)
FI (1) FI3880818T3 (ru)
HR (1) HRP20221358T1 (ru)
HU (1) HUE060703T2 (ru)
IL (1) IL283159A (ru)
LT (1) LT3880818T (ru)
MA (1) MA58208B1 (ru)
MX (1) MX2021005590A (ru)
PE (1) PE20211282A1 (ru)
PH (1) PH12021550801A1 (ru)
PL (1) PL3880818T3 (ru)
PT (1) PT3880818T (ru)
RS (1) RS63778B1 (ru)
SG (1) SG11202103882QA (ru)
SI (1) SI3880818T1 (ru)
WO (1) WO2020099476A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018247925A1 (en) * 2017-04-05 2019-10-03 Silence Therapeutics Gmbh Products and compositions
HRP20230127T1 (hr) 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
PE20211282A1 (es) 2018-11-13 2021-07-19 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula
US20240035029A1 (en) 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CA3229020A1 (en) * 2021-09-14 2023-03-23 Stella PELENGARIS Treatment of cardiovascular disease
WO2023152194A1 (en) 2022-02-09 2023-08-17 Silence Therapeutics Gmbh Therapeutic inhibition of lpa expression
CN114703184A (zh) * 2022-03-11 2022-07-05 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US20060160759A1 (en) 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
AU2018247925A1 (en) 2017-04-05 2019-10-03 Silence Therapeutics Gmbh Products and compositions
CA3118327A1 (en) * 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
HRP20230127T1 (hr) * 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
PE20211282A1 (es) 2018-11-13 2021-07-19 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula

Also Published As

Publication number Publication date
MX2021005590A (es) 2023-01-24
JP2022507282A (ja) 2022-01-18
PH12021550801A1 (en) 2021-10-04
US20220002722A1 (en) 2022-01-06
KR102553386B1 (ko) 2023-07-07
JP7245328B2 (ja) 2023-03-23
EP3880818B1 (en) 2022-09-28
PL3880818T3 (pl) 2023-01-23
US11499153B2 (en) 2022-11-15
EP4219712A2 (en) 2023-08-02
BR112021009213A2 (pt) 2021-08-10
CN113227372A (zh) 2021-08-06
RS63778B1 (sr) 2022-12-30
HRP20221358T1 (hr) 2022-12-23
CO2021007372A2 (es) 2021-07-09
CR20210301A (es) 2021-09-16
US20220170016A1 (en) 2022-06-02
SI3880818T1 (sl) 2023-01-31
PT3880818T (pt) 2022-12-06
PE20211282A1 (es) 2021-07-19
WO2020099476A1 (en) 2020-05-22
CA3119239A1 (en) 2020-05-22
SG11202103882QA (en) 2021-05-28
KR20210095878A (ko) 2021-08-03
AU2019380628A1 (en) 2021-05-20
FI3880818T3 (fi) 2022-12-15
MA58208B1 (fr) 2022-12-30
IL283159A (en) 2021-06-30
EP3880818A1 (en) 2021-09-22
ES2932295T3 (es) 2023-01-17
CL2021001225A1 (es) 2021-12-24
DK3880818T3 (da) 2022-12-05
EP4219712A3 (en) 2023-11-22
HUE060703T2 (hu) 2023-04-28
LT3880818T (lt) 2022-12-27

Similar Documents

Publication Publication Date Title
EA202190895A1 (ru) Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке
ZA202003371B (en) Nucleic acids for inhibiting expression of lpa in a cell
PH12020500622A1 (en) 17á-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
EA201792263A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP4219713A3 (en) Products and compositions
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2018005096A (es) Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022007005A (es) Construcciones de iarn y metodos para inhibir la expresion de lpa.
MX2019002271A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MX2021003845A (es) Composiciones para reducir el acido urico serico.
MX2022013606A (es) Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
WO2016205323A8 (en) Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
EA202091520A1 (ru) Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
Harada et al. Inorganic polyphosphate suppresses lipopolysaccharide-induced inducible nitric oxide synthase (iNOS) expression in macrophages
EP3483271A3 (en) Products and compositions
WO2020060987A8 (en) Complement component c5 irna compositions and methods of use
MD3880818T2 (ro) Acizi nucleici pentru inhibarea expresei LPA într-o celulă
BR112017021485A2 (pt) oligonucleotídeo antissentido isolado, composição farmacêutica, métodos para induzir salto de éxon de um rna de sarcoglicano gama, para aliviar distrofia muscular de cinturas tipo 2c, para inibir a progressão de patologia distrófica associada a lgmd2c e para aprimorar função muscular, e, kit.
Gebraad et al. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
EA202092092A1 (ru) Фармацевтические композиции с высокими лекарственными нагрузками среднецепочечных триглицеридов и связанные с ними способы
EA202092226A1 (ru) КОМПОЗИЦИИ иРНК 17-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 13 (HSD17B13) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ